טוען...
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
BACKGROUND: Regulators and payers have to strike a balance between the needs of the patient and the optimal allocation of resources. Drugs indicated for rare diseases (orphan medicines) are a special group in this context because of their often high per unit costs. Our objective in this pilot study...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2805618/ https://ncbi.nlm.nih.gov/pubmed/20003427 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1750-1172-4-27 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|